Given that increased AR expression has been associated with poorer prognosis in some of these cancers (early-stage hepatocellular carcinoma and colon cancer), these results suggest that these pathways may serve as effective therapeutic targets across multiple cancers, including head and neck cancer and breast cancer [56,57]. The gene discussed is AR; the disease is cancer.